Drug Supply Chain Security Act
Title II of the Drug Quality and Security Act (Pub. L. 113-54, 2013), codified at FD&C Act §§581–585. It builds an interoperable, electronic, package-level system for tracing prescription drugs through the US supply chain, and defines who may be a trading partner at all.
What this does not cover
stated in the document's own scope- Covers prescription drugs in finished form in the US supply chain; many medical devices, and products such as certain compounded preparations, blood, and some others, are outside or partly outside its tracing scope.
- Governs supply-chain tracing, trading-partner status, and suspect-product handling, not the manufacturing quality of the drug itself, which is set by cGMP (21 CFR Parts 210–211).
- Provides a national tracing standard and pre-empts inconsistent state pedigree laws, but leaves other aspects of state pharmacy and wholesale-distributor licensing in place.
Always verify against the current published text before relying on it for a submission or inspection.
Overview
The Drug Supply Chain Security Act is Title II of the Drug Quality and Security Act, codified at Sections 581–585 of the Federal Food, Drug, and Cosmetic Act. It establishes a national system to trace prescription drugs through the US supply chain and to keep illegitimate product out of it. The Act defines who may lawfully be a trading partner, requires product identifiers at the package level, mandates the exchange of transaction information as product changes hands, sets duties to investigate and handle suspect and illegitimate product, and builds toward an interoperable, electronic, package-level tracing system phased in over roughly a decade.
Scope & applicability
Manufacturers, repackagers, wholesale distributors, third-party logistics providers, and dispensers handling prescription drugs in the US supply chain.
Legal basis & how it acquires force
DSCSA is federal statute — Title II of the Drug Quality and Security Act, Public Law 113-54, enacted in 2013 — inserted into the Federal Food, Drug, and Cosmetic Act at §§581–585. It pre-empts a patchwork of differing state pedigree laws with a single national standard administered by FDA. Its requirements phased in over time, with the enhanced, interoperable, electronic, package-level tracing obligations reaching their milestone in the 2023–2025 window; FDA has used stabilization periods and exemptions to smooth that transition, so specific compliance dates should be confirmed against current FDA announcements.
Document structure
| Part | Covers |
|---|---|
| §581 Definitions | Key terms including trading partner, transaction information, product identifier, and suspect/illegitimate product |
| §582 Requirements | Trading-partner, product-tracing, verification, and suspect/illegitimate-product duties, phased by trading-partner type |
| §583 Waivers, exceptions, exemptions | Waivers and exemptions from the requirements where appropriate |
| §584 Standards for interoperable exchange | Standards for the interoperable, electronic exchange of tracing information |
| §585 National uniformity | Pre-emption of inconsistent state and local product-tracing requirements |
Key requirements
- Exchange of transaction information and transaction statements in an interoperable electronic form
- Trading only with authorised trading partners, verified and documented
- Systems and processes to investigate suspect product and notify FDA and trading partners for illegitimate product
- Product identifiers applied at package and homogeneous case level, and verifiable
Implementation tips
- Treat the serialisation data as GxP data — it is subject to the same integrity expectations as any other regulated record
- Test interoperability with actual trading partners rather than against the specification alone; the failures surface at the interface
- Map your own trading-partner category to its applicable exemption date before scoping remediation work
Where this control fails
live FDA enforcementLive FDA recalls SPEQ maps to this standard’s topics — a SPEQ interpretation, not an FDA classification.
International alignment
DSCSA is a US supply-chain-security statute that pursues the same traceability goal as the European Falsified Medicines Directive and its Delegated Regulation, though through a different architecture and identifier flow. On identifier syntax it relies on GS1 standards (such as the GTIN and serialized data carried in a 2D barcode) rather than defining its own. It complements, rather than replaces, the good distribution and manufacturing practices that govern product quality across the supply chain.
DSCSA (FD&C Act §§581–585): frequently asked questions
Quick answers to common questions about DSCSA (FD&C Act §§581–585).
What does the DSCSA require?
It builds an interoperable, electronic, package-level system to trace prescription drugs through the US supply chain — defining lawful trading partners, requiring product identifiers and the exchange of transaction information, and setting duties to investigate suspect and illegitimate product.
Where is the DSCSA codified?
It is Title II of the Drug Quality and Security Act (Public Law 113-54, 2013), codified in the Federal Food, Drug, and Cosmetic Act at Sections 581 through 585.
Does the DSCSA use GS1 standards?
For identifier syntax, yes — DSCSA relies on GS1 identifiers such as the GTIN and serialized data carried in a 2D barcode rather than defining its own numbering scheme, while the Act itself sets the tracing and trading-partner requirements.
This standard in practice
Recall domain is a SPEQ mapping of this standard’s topics, not an FDA classification.